Catalent (NYSE:CTLT) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of Catalent (NYSE:CTLT) from a hold rating to a sell rating in a report released on Friday morning.

CTLT has been the topic of several other research reports. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Stock Performance

CTLT opened at $60.98 on Friday. The business has a 50 day moving average price of $59.81 and a two-hundred day moving average price of $58.31. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The company has a market capitalization of $11.07 billion, a price-to-earnings ratio of -26.98, a price-to-earnings-growth ratio of 2.37 and a beta of 1.16. Catalent has a 1-year low of $36.74 and a 1-year high of $61.50.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.10) EPS. Research analysts predict that Catalent will post 0.84 EPS for the current fiscal year.

Insider Buying and Selling at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 in the last three months. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CTLT. Gamco Investors INC. ET AL grew its holdings in shares of Catalent by 403.3% during the 1st quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock valued at $1,428,000 after acquiring an additional 20,273 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Catalent by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock valued at $24,550,000 after purchasing an additional 14,373 shares in the last quarter. Quest Partners LLC increased its position in Catalent by 289.8% in the 3rd quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock worth $2,986,000 after purchasing an additional 36,652 shares during the last quarter. Swedbank AB purchased a new stake in shares of Catalent during the 1st quarter worth about $1,659,000. Finally, New York Life Investment Management LLC lifted its holdings in shares of Catalent by 67.9% during the 2nd quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock valued at $16,751,000 after buying an additional 120,502 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.